Daniel Haraf to Risk Assessment
This is a "connection" page, showing publications Daniel Haraf has written about Risk Assessment.
Connection Strength
0.098
-
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
Score: 0.042
-
AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck. 2017 02; 39(2):201-205.
Score: 0.018
-
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
Score: 0.011
-
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4.
Score: 0.010
-
Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
Score: 0.009
-
Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol. 2003 Aug; 14(8):1306-11.
Score: 0.007